PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV

GLP-1 Drugs and Muscle Loss: What the Clinical Trials Actually Show

7:20Mar 2026

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

According to the video, semaglutide, tirzepatide and retatrutide create a calorie deficit mainly by suppressing appetite and slowing gastric emptying. The speaker says the body draws on both fat and lean mass during any sustained deficit, so people on these drugs may lose more lean mass if no exercise is added. The speaker presents this as a reason to know what to add, not a reason to avoid the drugs when they are clinically appropriate.

Published by Barbell Medicine on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

The video cites average weight loss of about 15% of starting body weight for semaglutide and about 20% for tirzepatide. It then reports DEXA lean mass shares of roughly 39% of weight lost in STEP 1 (semaglutide, 68 weeks), about 24% in SURMOUNT-1 (tirzepatide) and around 33% for retatrutide. The speaker argues these figures likely overstate true muscle loss, because DEXA counts water, glycogen and intramuscular fat as lean mass. The speaker points to the SURPASS 3 MRI substudy, which showed less intramuscular fat on tirzepatide than on placebo. The speaker also cites improved handgrip strength and lower sarcopenic obesity prevalence in the SEMALIN study. The BELIEVE trial of bimagrumab with semaglutide is described as showing 93% of weight loss from fat mass, against 72% with semaglutide alone.

The second half addresses public debate. The speaker says about one in 10 people in intensive lifestyle programs keep clinically significant weight loss at 5 years, and criticizes the claim that these drugs consume muscle. The speaker recommends about 1.6 g of protein per kilogram of body weight per day and progressive resistance training, and says the risks of the drugs and of untreated obesity should be weighed together.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:00 The speaker says GLP-1 drugs cut calories mainly through appetite suppression and delayed gastric emptying, so lean mass can be lost along with fat.
  2. 1:01 The video reports DEXA lean mass shares of about 39% for semaglutide in STEP 1, about 24% for tirzepatide in SURMOUNT-1 and around 33% for retatrutide.
  3. 2:03 The speaker argues DEXA likely overstates muscle loss because it counts fluid, glycogen and intramuscular fat, citing the SURPASS 3 MRI substudy and SEMALIN handgrip data.
  4. 3:04 The speaker cites the BELIEVE trial of bimagrumab with semaglutide, and recommends about 1.6 g of protein per kilogram per day plus progressive resistance training.
  5. 4:36 The speaker says only about one in 10 people in intensive lifestyle programs maintain clinically significant weight loss at 5 years.
  6. 6:38 The speaker concludes that the muscle loss concern deserves attention but must be weighed against the risks of untreated obesity.

Key moments

Tap one to play from there.

  1. 0:00 GLP-1s Don't Use the Same Pathways as Exercise
  2. 0:19 The Weight Loss Numbers: Semaglutide vs. Tirzepatide
  3. 0:40 The Trial Data: What DXA Actually Measured
  4. 1:18 Why Those Lean Mass Percentages Are Overstated
  5. 1:48 The MRI Evidence: Myosteatosis Reduction on Tirzepatide
  6. 2:05 Functional Data: Handgrip Strength and Sarcopenic Obesity
  7. 2:28 The BELIEVE Trial: 93% of Weight Loss From Fat
  8. 3:05 What to Do If You're on a GLP-1

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
semaglutide, tirzepatide and retatrutide
Side effects mentioned
muscle loss

Questions this video answers

How much of the weight lost on semaglutide or tirzepatide is muscle?

The video cites DEXA data showing about 39% of weight lost was lean mass in STEP 1 (semaglutide) and about 24% in SURMOUNT-1 (tirzepatide). The speaker says these figures likely overstate actual skeletal muscle loss because DEXA also counts water, glycogen and intramuscular fat as lean mass.

Why might DEXA overstate muscle loss on GLP-1 drugs?

According to the speaker, DEXA treats everything that is not fat or bone as lean mass, including water, glycogen, organ tissue and intramuscular fat. The speaker says shifts in fluid and glycogen during rapid weight loss, and loss of intramuscular fat, get recorded as lean mass loss.

What can people on GLP-1 drugs do to preserve muscle?

The speaker recommends adequate protein, about 1.6 g per kilogram of body weight per day, and progressively loaded resistance training. The speaker also describes the BELIEVE trial, where adding bimagrumab to semaglutide was associated with 93% of weight loss coming from fat mass.

What does the video say about the muscle loss concern around GLP-1 drugs?

The speaker says the concern is real but that the idea these drugs consume muscle does not hold up against the evidence. The speaker argues the risks should be weighed against the effects of untreated obesity.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • GLP-1 muscle loss: how much of the weight is muscle, and what protects it

    On semaglutide or tirzepatide, roughly a quarter to two fifths of the weight you lose is lean mass rather than fat: 25% in tirzepatide's SURMOUNT-1 scan substudy, and 25% to 39% across 20 randomised trials. That share is close to what diet-only weight loss costs. Lean mass is not all muscle, and strength held up in the shorter trials. Resistance training cut the lean share to 17.5% in the pooled trials, and expert groups pair it with enough protein.

  • Stopping a GLP-1: what the withdrawal trials found, and what a maintenance dose actually is

    Two trials have measured what happens when you stop. On semaglutide, people who lost 17.3% over 68 weeks regained two-thirds of it in the year after stopping, ending 5.6% below where they started. On tirzepatide, people who lost 20.9% in 36 weeks regained 14% over the next year on placebo while those who continued lost a further 5.5%. Both labels are explicit that these drugs are for maintaining weight reduction long term, which is a different claim from finishing a course. A maintenance dose is simply the dose you stay on; the labels do not define a lower one to step down to at goal.

  • GLP-1 vs GLP-2 vs GLP-3: what the names mean, and which ones you can actually buy

    GLP-1 drugs such as semaglutide act on one receptor. "GLP-2" is used online for tirzepatide (Zepbound, Mounjaro), which acts on two, GIP and GLP-1, and "GLP-3" for retatrutide, which adds the glucagon receptor. Neither nickname is the real name: GLP-2 is a separate gut hormone whose drug, Gattex, treats short bowel syndrome. Retatrutide produced 28.3% mean weight loss at 80 weeks in its phase 3 trial but is not FDA-approved; Lilly plans to file in Q1 2027. Tirzepatide is the strongest option you can buy today.

Next steps

Compounded semaglutide prices

Find more like it

Food, protein and eatingExercise and strengthThe trialsMuscle loss

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV